The BioHub: The Top Voices in Biotech

In this episode of The BioHub, I’m joined by Catherine Isted, Chief Financial Officer of Santhera Pharmaceuticals.Catherine’s career journey is a unique one, from starting as a bench scientist, to nearly two decades in healthcare investment banking, and now leading finance at multiple biotech companies.In this International Women’s Day special, we talk about her path through the industry, the importance of diversity of thought in biotech, her experiences building a career in leadership, and her advice for young women looking to enter the field.

Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes.Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expand their portfolio, grow their footprint, and continue delivering life-changing treatments for patients with rare neuromuscular and neurological diseases.We talk about what drew him to Catalyst, how the company thinks about growth, patient service, and rare-disease strategy, how they find the right drugs in a competitive market, and how Catalyst continues to outperform despite the volatility across biotech.Let’s get into it.

We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub. Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema. Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak Sciences, where he led clinical development in retinal disease. Earlier in his career, he held senior leadership roles at Genentech, one of the pioneers in biologic medicines, helping advance therapies that have transformed care for patients with vision-threatening conditions.Trained as both a physician and a scientist, Jason brings arare blend of clinical insight, translational research expertise, and strategic leadership. His career sits at the intersection of medicine, innovation, and company building — with a clear focus: delivering meaningful, durable therapies to patients who risk losing their sight.

In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical.Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s happening at Vivani right now, and what it takes to build and finance a biotech company in today’s market.

Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy.Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in immune-based therapies.Across his career, Terry has held senior scientific and leadership roles at major biopharmaceutical organizations including Amgen, Pfizer, and Abbott Laboratories, building a track record that bridges rigorous medicinal chemistry with bold company creation.In this we discuss:Arcus' pipeline and what makes them stand out from other companies in the immuno-oncology fieldWhat makes Arcus a compelling investment opportunity today and how they balance the long timelines and risks of drug development with the expectations of public markets and investors?The key milestones for Arcus in the next year to18 months that the scientific and investment communities should be paying attention to

In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics.Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals.We talk about his journey into the industry, the science and vision behind Perspective, the company’s recent $175M raise, and the milestones that could define their next phase of growth. A great conversation about bold strategy, differentiated science, and building momentum in today’s market.

We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies.Throughout his career, he has played a pivotal role in advancing innovative therapies from early discovery through to global commercialization. At Causeway Therapeutics, he is leading the charge in developing breakthrough treatments aimed at addressing serious and underserved medical needs.In this we discuss:Entrepreneurship and building a biotech having spent decades in PharmaCauseway's recent encouraging clinic results and what makes there approach different to what's out there alreadyHow Causeway are thinking about the pipeline and upcoming milestones

In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture.Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify.We talk about starting companies from zero, building the right teams early, de-risking new ventures, and the realities of fundraising in today’s biotech market. A practical, honest conversation with a true biotech builder.

We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs.Over the years, Simeon has helped build and back some of the most impactful companies in modern biotech, including CRISPR Therapeutics, Turning Point Therapeutics, and Principia Biopharma, among many others. He’s also a co-founder and board member of multiple biotech companies, working closely with scientists and founders to bring new medicines to patients

Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent.Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial services, holding senior HR leadership roles at organizations like the Broad Institute of MIT and Harvard, Warp Drive Bio, Aegerion Pharmaceuticals, and several major financial institutions.In this we discuss:Kim's 8.5 year journey so far at Fulcrum, from a small, ambitious biotech to the more mature, resilient organization it is today.Restructuring and the lessons learnt about leadership,communication, and empathy during times of crisisKim's new book 'The Culture Shock'

In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics.Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies.We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset, leadership, and what it really takes to build in small biotech.

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.In this we cover: The spark that led to the founding of Enara BioEnara's platform EDAPT® and how it finds dark antigens in tumors.Where the field of T-Cell therapy for solid tumors is today.The importance of culture in early stage biotech, and how the company has been built around putting people first.The next major milestones for Enara Bio.

JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon BioIn this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer, CEO and Founder of Hexagon Bio.Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform company in today’s market — from scientific conviction and capital discipline to leadership, culture, and long-term vision.We also discuss:What makes Hexagon’s approach fundamentally differentHow Maureen thinks about risk, focus, and scale as a founder-CEOThe realities of building biotech through multiple market cyclesA thoughtful, grounded conversation with one of the most impressive founders in the space.

I’m here with Mike Exton, the CEO of LexiconPharmaceuticals.Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto.Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need.Mike, great to have you here

In our first JPM Special 2026, we’re joined by Dirk Thye, CEO of Quince Therapeutics, as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech.

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early discovery to clinical development. At Delphia Therapeutics, Kevin is leading the development of a new approach to precision oncology known as activation lethality—an emerging strategy designed to uncover previously untapped cancer vulnerabilities and deliver more targeted, effective treatments. With a background that blends rigorous science, entrepreneurial leadership, and a patient-first mindset, Kevin brings a thoughtful perspective on the future of cancer therapy, innovation in biotech, and what it truly takes to build a science-driven company from the ground up. We’re excited to have him with us today.

Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases.With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs.Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.

We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio, a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub!Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag Bio, he heldsenior executive roles at several innovative life-science companies, including bluebird bio, where he served in multiple leadership positions across strategy, operations, finance, and legal affairs. He has also led and advised emerging biotech companies as both a CEO and board member.At Zag Bio, Jason is leading a bold effort to rethinkhow autoimmune diseases are treated. Their work aims to address the root cause of autoimmunity, with the potential for more durable and transformative therapies.We’re excited to talk with Jason today about his careerjourney, the science behind Zag Bio, and what it takes to build the next generation of biotech innovation.

Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences.Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia. Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies.In this conversation, we get into what inspired him to join Pacira, how the company has evolved, and how they’ve aligned the entire organization around a clear and bold mission. We also dive into leadership, culture, and the future of pain management.Let’s get into it.

Welcome to The BioHub Podcast.I’m joined by Luba Greenwood, CEO of Gallop.Luba’s one of the most respected voices in biotech — a three-time CEO, founder of Binney Street Capital at Dana-Farber, and a driving force behind Biotech Hangout.We talk about Gallop’s mission, what it takes to build strong culture in tough markets, and the personal motivation behind her work after losing her mum to cancer.It’s an inspiring and powerful conversation — let’s get intoit.